PMID-24843641 – GIP and GLP-1 Incretin Actions Beyond Pancreas
Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action," Cell Metab, 2013;17(6):819-837.
Quick Reference
| Property | Value |
|---|---|
| PMID | 24843641 |
| DOI | 10.1016/j.cmet.2013.04.008 |
| Year | 2013 |
| Journal | Cell Metabolism |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (review) |
| Peptide(s) Studied | GIP, GLP-1 (Native) |
Key Findings
- Both GIP and GLP-1 are rapidly degraded by dipeptidase DPP-4 (GIP half-life ~5-7 min, GLP-1 half-life ~2-3 min), driving development of DPP-4 resistant analogs
- GIP and GLP-1 act on distinct but complementary receptor systems; GIP primarily via GIPR on beta cells and adipocytes, GLP-1 via GLP-1R on beta cells, brain, and heart
- Beyond insulin secretion: GIP promotes adipocyte lipid uptake and triglyceride storage; GLP-1 suppresses appetite, slows gastric emptying, and has cardioprotective effects
- GIP promotes bone formation via GIPR on osteoblasts — postprandial GIP release helps couple nutrient absorption to bone anabolism
- GLP-1 has neuroprotective effects and GLP-1R agonists are being investigated for Alzheimer's and Parkinson's disease
- The incretin effect is reduced in T2D: GIP resistance develops (beta cell GIPR downregulation), while GLP-1 retains partial activity — this is why early GLP-1-only drugs were developed first
- Combination targeting of both incretin pathways (as with tirzepatide) may overcome GIP resistance through pharmacological doses
Study Design
Review article in Cell Metabolism synthesizing molecular, cellular, animal, and clinical data on GIP and GLP-1 biology, covering receptor mechanisms, extrapancreatic actions, and therapeutic implications.
Limitations
- Published 2013; predates tirzepatide clinical data and the renaissance of GIP agonism
- GIP's role in adipose metabolism was controversial at time of publication
- Some extrapancreatic incretin effects were based primarily on preclinical data
Clinical Relevance
This Cell Metabolism review by the same group (Campbell & Drucker) provides the earlier foundational framework for understanding incretins beyond the pancreas. It explains why the incretin effect is impaired in T2D (particularly GIP resistance) and why pharmacological doses of GIPR agonists (as in tirzepatide) may overcome this resistance. The extrapancreatic effects — bone formation, neuroprotection, cardiovascular protection — are increasingly recognized as clinically relevant benefits of incretin-based therapies beyond glucose control and weight loss.
Related
#research #narrative-review #evidence-level-V #metabolic #GIP #GLP-1 #endogenous #incretin